股票行情快报：尚荣医疗（002551）2月5日主力资金净卖出214.98万元

Core Viewpoint - The financial performance of Shangrong Medical (002551) has significantly declined, with a notable drop in revenue and net profit for the first three quarters of 2025 compared to the previous year [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 754 million yuan, a decrease of 24.85% year-on-year [2]. - The net profit attributable to shareholders was -35.13 million yuan, down 338.5% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was -42.33 million yuan, a decline of 1336.59% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 225 million yuan, a decrease of 39.25% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -27.37 million yuan, down 4004.28% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was -29.81 million yuan, a decline of 2776.04% year-on-year [2]. - The company's debt ratio stood at 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [2]. - The gross profit margin was 14.35% [2]. Market Activity - As of February 5, 2026, Shangrong Medical's stock closed at 3.85 yuan, down 0.52% [1]. - The turnover rate was 1.48%, with a trading volume of 90,500 hands and a transaction amount of 34.98 million yuan [1]. - On February 5, the net outflow of main funds was 2.15 million yuan, accounting for 6.15% of the total transaction amount [1]. - The net inflow of retail funds was 2.03 million yuan, representing 5.8% of the total transaction amount [1].